Banka BioLoo Limited has informed the Exchange regarding Outcome of Board Meeting held on August 08, 2025.
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Banka BioLoo's board approved unaudited Q1 FY26 results (quarter ended June 30, 2025) with a clean limited review from auditors B.D. Saboo & Associates. Standalone revenue from operations rose modestly to Rs 1,255.82 lakhs (vs Rs 1,238.75 lakhs in Q1 FY25, about 1.4% growth), but total expenses climbed 12.6% to Rs 1,359.04 lakhs, squeezing profit before tax down to just Rs 2.12 lakhs (vs Rs 50.84 lakhs YoY). Standalone profit after tax fell about 68% YoY to Rs 13.54 lakhs, and EPS dropped to Rs 0.12 from Rs 0.39. Consolidated Q1 PAT was a marginal Rs 0.21 lakhs. The board also cleared re-appointment of Mr. Sanjay Banka as Executive Chairman, Mr. Vishal Murarka as CEO for 3 years, Dr. Basava Raju Dumpala as Independent Director for a second 5-year term, and appointed Mrs. Geeta Goti as a new Woman Independent Director. The 13th AGM is set for September 10, 2025 via video conferencing. FY25 audited results (already approved earlier) showed a standalone net loss of Rs 929.64 lakhs.
Sharp margin compression in Q1 FY26 — expenses grew much faster than revenue, dragging profits down roughly 68% YoY despite topline stability. This is a negative earnings quality signal for shareholders, though the company swung back to a small profit after a loss-making Q4 FY25.